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Abstract 
Objective: Episodes of acute adrenal insufficiency (AI)/adrenal crises (AC) are a serious consequence 
of congenital adrenal hyperplasia (CAH).  This study aimed to assess morbidity from acute illness in 
CAH and identify factors associated with use of IV hydrocortisone, admission and diagnosis of an 
AC.   
  
Method: An audit of acute illness presentations among children with CAH to paediatric hospitals in 
New South Wales, Australia, between 2000 and 2015. 
 
Results: There were 321 acute presentations among 74 children with CAH.  Two thirds (66.7%, 
n=214) of these resulted in admission and 49.2% (n=158) of the patients received intravenous (IV) 
hydrocortisone.  An AC was diagnosed in  (9.0%).  Prior to presentation, 64.2% (n=206) had used 
oral stress dosing and 22.1% (n=71) had been given intramuscular (IM) hydrocortisone.  Vomiting 
was recorded in 61.1% (n=196), 32.7% (n=64) of whom had used IM hydrocortisone.  Admission, 
AC diagnosis, and use of stress dosing varied significantly between hospitals.  IM use varied from 
7.0% in one metropolitan hospital to 45.8% in the regional hospital.  Children aged up to 12 months 
had the lowest levels of stress dosing and IV hydrocortisone administration.  A higher number of prior 
hospital attendances for acute illness was associated with increased use of IM hydrocortisone.  
 
Conclusion:  Pre-hospital and in-hospital management of children with CAH can vary between health 
services.  Children under 12 months have lower levels of stress dosing prior to hospital than other age 
groups.  Experience with acute episodes improves self-management of CAH in the context of acute 
illness in educated patient populations. 
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Introduction  
Congenital adrenal hyperplasia (CAH) is the most common cause of primary adrenal insufficiency 
(AI) in children (1-3). In Australia, the estimated CAH incidence is about one in 15,000, which is 
comparable to that in other countries (1-4). Approximately 95% of affected children have a deficiency 
of the enzyme 21-hydroxylase from the autosomal inheritance of inactivating mutations in both 
CYP21A2 alleles. This results in an impaired biosynthesis and secretion of cortisol, with or without 
aldosterone deficiency, in addition to elevated levels of adrenal androgens (3,5-7). Treatment of CAH 
involves the administration of glucocorticoid, both as a replacement therapy and to suppress ACTH 
stimulation, thereby reducing excess adrenal androgen production (3,5,6). Fludrocortisone is also used 
to treat aldosterone deficiency. 
All children with CAH are at higher risk of morbidity and mortality, some of which is 
attributable to potentially fatal adrenal crises (ACs) (5,6,8-10).
 
These acute events have an estimated 
incidence of between 4.9 and 10 ACs per 100 patient years (10,11). ACs are characterised by 
hypotension, electrolyte abnormalities, hypoglycaemia, vomiting, abdominal pain and a reduced level 
of consciousness. They occur when the physiological requirement for cortisol is greater than the 
amount in the circulation, typically during periods of physiological stress, such as an infection 
(1,3,5,7). Children with the more severe salt-wasting phenotypes are at a heightened AC risk. Those 
with less severe forms are also vulnerable during stress due to glucocorticoid-related suppression of 
the hypothalamic-pituitary axis (12). 
Cortisol dose escalation is regarded as the cornerstone of AC prevention in all forms of AI, 
including CAH (13-16). Parents and guardians are taught to increase their child’s dose of oral 
glucocorticoid during intercurrent illness or to administer an intramuscular (IM) injection when oral 
glucocorticoid therapy cannot be taken or absorbed. However, efforts by health professionals to 
educate carers and patients about the importance of stress dosing have not resulted in the elimination 
of ACs (17-19). Indeed, recent studies have shown that AC events continue to occur, even among 
well-educated AI patients (17,18).
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The reasons for the continued incidence of ACs in children with CAH are unknown. Various 
factors other than the effectiveness of AC prevention programs, such as psychosocial and cultural 
factors, health service availability, and clinical practices have been postulated but the basis for their 
continued occurrence remains unclear (9,17,20,21).
 
The aim of this study was to investigate the 
frequency, causes, severity and management of acute illness in a large sample of patients with CAH 
who presented to hospital.  
 
Subjects and Methods 
Three paediatric hospitals provide specialist healthcare to the 1.9 million children (22) in the state of 
New South Wales, Australia on a referral basis, in addition to providing general and specialist 
paediatric services to their local community. Two of these hospitals (A and B) are in metropolitan 
Sydney and the third (Hospital C) is in a large regional centre. Hospitals A and B have a practice 
guideline, which consists of a protocol for acute AI/AC management that includes instructions on the 
immediate administration of IM or IV hydrocortisone, fluid resuscitation and specific treatment of 
hypoglycaemia and abnormal electrolytes. By comparison, Hospital C uses a specific AI management 
sheet for each patient that is developed by their regular paediatric endocrinologist and paediatric 
endocrine nurse educator.  Information on all episodes of care in these hospitals is stored according to 
the patient’s medical record number (MRN) and includes demographic details; the principal 
diagnosis; whether the patient was treated in Accident and Emergency only or was admitted to 
hospital; and all comorbid diagnoses, which are coded according to the Australian modification of the 
International Statistical Classification of Diseases and Related Problems (ICD-10) (23).  
The MRNs of all children in each hospital who had at least one admission in which there was 
a record of a principal or comorbid diagnosis coded under the rubric E25.0 (Adrenogenital disorders 
associated with enzyme deficiency) were identified (23). All attendances at Accident and Emergency 
and admissions to hospital between January 2000 and December 2015 for patients up to 18 years of 
age were included. Only those children who were on glucocorticoid replacement therapy and had an 
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acute medical (non-surgical) illness that resulted in an unplanned attendance at hospital were selected 
for this analysis. 
All records were accessed electronically except for some of the earliest records for Hospital 
B, which were paper-based. Demographic information and data on the reason for attendance, type and 
length of stay, presenting symptoms and signs, diagnosis, use of stress dosing and management were 
collected.  
Ethics approval was granted by the Human Research and Ethics Committees of the Sydney 
Children’s Hospital Network (SCHN), John Hunter Children’s Hospital, and The University of Notre 
Dame, Australia.  
 
Data management 
Some symptoms were not documented in some medical records, possibly through omission.  Where 
this information was not found, it was assumed that the symptom was not part of that child’s 
presenting problem and that symptom was classified as absent. Similarly, where there was no blood 
chemistry, it was assumed that this represented a clinical decision not to take blood as the child was 
relatively well and these records were coded as normal. Hypotension was classified as either a blood 
pressure that was lower than the appropriate age-related boundary or a capillary return time of greater 
than 3 seconds and, where these values were absent, it was considered that the blood pressure was 
normal. Hyperkalaemia was defined as a serum potassium of greater than 5.0mmol/L, hyponatraemia 
as a serum sodium lower than 135mmol/L and hypoglycaemia as a blood glucose of less than 
3.5mmol/L (24).  In this analysis, an AC, which is usually characterised by hypotension, reduced 
consciousness and electrolyte abnormalities, was classified as present when this diagnosis was made 
by the treating doctor and entered into the medical record (14).  To add further information a variable 
representing the number of typical AC symptoms for each attendance was calculated.  This score 
comprised a count for each of hypotension, vomiting, diarrhoea, hyperkalaemia, hyponatraemia, 
hypoglycaemia, and reduced consciousness for a possible score of 7 points. 
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Stress dosing (either oral or IM) in this analysis refers to any administration prior to arrival at 
hospital. Fifty (15.6%) records did not include any information about the use of stress dosing. The 
proportion of complete records differed between the hospitals, with satisfactory documentation for 
96.3% (n=103) in Hospital C, 79.0% (n=124) for Hospital A and 77.2% (n=40) for Hospital B. Where 
these data were missing, that record was coded as not stress dosed.  One record stated that stress 
dosing had been used but the type was not specified.  
 
Statistical analysis 
Chi square and independent t-tests were used to assess group differences. Stepwise logistic regression 
models were developed to identify predictors of: an AC diagnosis; hospital admission; the use of any 
form of stress dose; oral stress dose use only; IM hydrocortisone administration; and the use of IV 
hydrocortisone in hospital. Statistical tests were conducted using SPSS (IBM SPSS Statistics for Mac, 
Version 24.0, Armonk, NY, USA).  A P-value of <0.05 was considered significant. 
 
Results 
There were 321 presentations for treatment of an acute medical illness by 74 children with CAH 
during the study period, corresponding to a median of 3 (IQR 2-7) presentations per child. Fifty-nine 
(79.9%) of these children had salt-wasting CAH. Two-thirds (66.7%, n=214) of the presentations 
were to the metropolitan hospitals [157 (48.9%) to Hospital A and 57 (17.8%) to Hospital B] and the 
remainder (n=107, 33.3%) were to the regional hospital (C). Two-thirds (66.4%) of the attendances 
resulted in admission; IV hydrocortisone was administered to 158 (49.2%) patients; and the median 
length of stay was 2 (IQR 1-3) days. An AC was recorded in 29 (9.0%) cases. There were no in-
hospital deaths; 8 (2.5%) children were admitted to an ICU; and one child developed a severe brain 
injury following hypoglycaemic seizure at home.   
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The median age of attendees was 3 (IQR 0-7) years. More than a third (39.3%, n=126) of the 
patients were in the age group 1-4 years (Table 1).  An infection was diagnosed in 42.7% (n=137), 
with 52 (16.2%) having a diagnosis of gastroenteritis (Table 1). More infections were identified as 
viral (34.0%, n=109) than bacterial (5.3%, n=17).  Hypotension was noted in 5.9% (n=19) and 11.8% 
(n=38) had reduced consciousness/unconsciousness. Hyponatraemia was more common than 
hyperkalaemia (12.8%, n=41 and 6.2%, n=20 respectively). Hypoglycaemia was identified in 27 
(12.4%) of the patients and a seizure was reported in 13 (4.1%). The most common symptom was 
vomiting, which was reported in 196 (61.1%) of the attendances, while diarrhoea was recorded in 78 
(24.3%) and a prodromal illness was noted in 189 (58.9%) (Table 1). The mean number of signs and 
symptoms per presentation to hospital was 1.21±0.94 and this did not differ significantly between the 
hospitals (Table 2). A diagnosis of AC was significantly associated with hypoglycaemia [24.1% (n=7) 
of those with an AC compared with 6.8% without (n=20), P<0.01]; a reduced level of 
consciousness/unconsciousness [36.8% (n=14) of patients with a reduced level consciousness were 
diagnosed with an AC compared with 5.3% (n=15) of those without (P<0.001)] and lethargy [62.1% 
(n=18) of AC patients were lethargic compared with 28.8% (n=84) of those who were not, P<0.001].  
The mean number of signs and symptoms of AI was significantly higher in patients with an AC 
diagnosis than those without (1.93±1.00 vs. 1.14±0.90, p<0.001). 
 
Stress dosing was used by 64.2% (n=206) of the patients; 41.7% (n=134) used oral 
glucocorticoid dose escalation only and 22.1% (n=71) used IM hydrocortisone with or without oral. 
Among patients with a prodromal illness, 68.8% (n=130) used stress doses, as did 74.0% (n=145) of 
those with a history of vomiting and 75.6% (n=59) of patients with diarrhoea (Table 3). One third 
(32.7%, n=64) of the children with vomiting were given IM hydrocortisone prior to hospital 
attendance, with 41.3% (n=81) using oral only (Table 3). Similarly, fewer patients with diarrhoea 
used IM hydrocortisone (24.4%, n=19) than oral (51.3%, n=40) (Table 3). IM hydrocortisone use was 
significantly associated with the diagnosis of an AC (18.3% (n=13) of patients using IM were 
classified as having an AC compared with 6.4% (n=16), p<0.01). By comparison, there was no 
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significant association between oral stress dose use or use of all types of stress dose and AC incidence 
(both p>0.05). 
AC incidence did not differ by age group but use of stress dosing did (P<0.02), being used 
most commonly in children aged 1-4 years (73.0%, n=92). By comparison, both IM and IV 
hydrocortisone use varied significantly by age group (p<0.04 and <0.03, respectively), and were used 
more often in older patients (Table 1).  Children aged 1-4 years had the highest levels of prodromal 
illness (67.5%, n=85) and the lowest proportion (58.7%, n=74) of admissions (Table 1). 
Hyperkalaemia was more common in children under 12 months (17.3%, n=14) (Table 1).   
Admission for acute illness and use of stress dosing varied significantly by hospital (p<0.001 
and p<0.01, respectively).  Hospital C admitted the largest proportion (80.4%, n=86) of patients and 
had the highest proportion of patients using stress doses (75.7%, n=81) (Table 2). Patients who were 
admitted had a significantly higher mean number of signs and symptoms of AI than those who were 
treated as outpatients only (1.35±0.92 vs. 0.93±0.92,p<0.001) (Table 4). There were also substantial 
differences between the hospitals in the use of IM hydrocortisone (p<0.001), with 45.8% (n=49) of 
the patients at Hospital C using IM hydrocortisone compared with 7.0% (n=11) of the patients in 
Hospital A (Table 2).  This difference was maintained even when only those records in which there 
was a definitive note of stress dosing were included (47.6% compared to 8.8%, p<0.01).  ACs were 
most commonly recorded in patients attending Hospital C (15.9%, n=17) (p<0.01) and this hospital 
had the highest use of IV hydrocortisone (69.2%, n=74) (p<0.001).  
 
Predictors of AC and CAH management 
Logistic regression analysis showed that an AC diagnosis was significantly associated with two 
factors: the treating hospital [Hospital B vs A: OR (95% CI) 4.42 (1.25-15.65)] and Hospital C vs A:  
OR (95% CI) 4.63 (1.65-12.94)] and with the presence of a reduced level of 
consciousness/unconsciousness [OR (95% CI) 11.27 (4.57-27.80)] but not the number of AC signs 
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and symptoms (Table 5). Admission was also significantly associated with the treating hospital; 
number of signs and symptoms [OR (95% CI) 1.64 (1.24-2.17)]; and patient age (Table 5). 
The use of any type of stress management strategy (either oral or IM) prior to hospital 
attendance was associated with the treating hospital; vomiting [OR (95% CI); 2.50 (1.52-4.10)]; and a 
diagnosis of gastroenteritis [OR (95% CI): 2.67 (1.17-6.09)] (Table 5).  By comparison, oral stress 
dosing was associated with a prodromal illness [OR (95% CI) of 2.43 (1.49-3.96)] and hospital, with 
hospitals B and C having a lower likelihood of oral stress dosed patients than hospital A (Table 5).  
IM hydrocortisone use was related to the number of previous attendances for an acute illness 
[(OR (95% CI) for each additional presentation: 1.11 (1.03-1.20)] but not the child’s age.  It was also 
predicted by a history of vomiting and gastroenteritis but was negatively associated with a history of 
prodromal illness (Table 4). The treating hospital was also predictive of IM hydrocortisone use, with 
the regional hospital having an OR of 9.65 (95% CI 4.43-21.00) relative to Hospital A (Table 5).   
Hospital was also associated with IV hydrocortisone use [OR of 2.47 (95% CI: 1.39-4.37) for 
Hospital C compared with A]. In addition, vomiting was associated with IV hydrocortisone 
administration, as was the increased number of signs and symptoms of acute AI (Table 5).  Increasing 
age was also associated with IV hydrocortisone treatment [OR for each year of age of 1.10 (95% CI 
1.04-1.16)] (Table 5).  
 
Discussion 
The results of this comprehensive study of morbidity in paediatric CAH demonstrate that affected 
children experience significant illness episodes and that AC events still occur, being diagnosed in 9% 
of the hospital attendees.  Two-thirds of the presentations resulted in admission and IV hydrocortisone 
was administered to half the children who attended hospital. Overall, glucocorticoid stress 
management of any kind was used by 64.2% of the patients, with exclusively oral dose escalation 
employed by 41.7% and parenteral hydrocortisone used by 22.1%. While there were some differences 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
in presentation and treatment according to the age of the child, greater variation was found between 
the hospitals with regards to both pre-hospital management and in-hospital care. Use of IM 
hydrocortisone was positively associated with the number of previous hospital attendances for acute 
care. Treatment in hospital was successful, as there were no in-hospital deaths, although one child 
sustained a neurological injury. 
In this study, the incidence of ACs differed significantly between the hospitals.  This variation 
may be due to patient factors, severity of illness, or more probably reflects differences between 
clinicians in the classification of AI-related illness as an AC.  Disparities between clinicians appears 
in this study to be more likely given that the symptom scores did not differ between the hospitals, 
although differences in severity of individual symptoms were not assessed. The definition of an AC 
has been shown to vary substantially between studies in both adult and paediatric patients, 
encompassing the classification of relatively mild illness as an AC to the inclusion of only severe 
episodes (9,14-16). Cardiovascular compromise, manifest by hypotension or other features of 
circulatory collapse in children, is generally agreed to be the key physiological feature of an AC (14-
16,25).
 
 However, in this study, hypotension was not significantly associated with an AC diagnosis 
and was reported in fewer than 6% of the patients. Electrolyte abnormalities and hypoglycaemia are 
also common features of an AC in children (15) but there was a relatively low incidence of those in 
this study. Although hypoglycaemia was found to be associated with an AC on bivariate analysis, it 
was not a significant predictor of AC in multivariate logistic regression models due to its association 
with reduced consciousness/unconsciousness, which was the only predictor, other than the treating 
hospital, of an AC diagnosis.  
Patient age was associated with the management of symptomatic AI in this study, with stress 
management strategies used less commonly by parents of children under 12 months than those with 
older children. Similarly, IV hydrocortisone was given less often to children in the youngest age 
group than to older patients. This suggests that parents are less able to manage intercurrent illness in 
their very young children and are more reliant on assistance from a health service than parents of 
older children. These results are consistent with research by Fleming et al. (21), which demonstrated 
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that the parent’s confidence and their ability to assess the severity of their child’s illness were integral 
to their capacity to manage an acute illness episode. Improvement in the child’s ability to articulate 
their symptoms with increasing age was also found to assist the family’s management of the illness 
(21). Paradoxically, there were higher rates of IV hydrocortisone use in adolescents in this study, 
which may reflect non-adherence to their glucocorticoid regimens, as older children with CAH 
attempt to take a greater role in managing their own treatment (2,26).
 
While gastroenteritis was formally diagnosed in 16.2% of the children, vomiting which is also 
a symptom of symptomatic AI or an AC, was present in a substantially more (61.1%) patients and 
was significantly associated with hospital admission.  Previous reviews have emphasised the 
importance of parenteral glucocorticoids in the context of vomiting, as this symptom can preclude or 
impair the absorption of oral therapy (15-17,26). Although vomiting was a predictor of both IM and 
IV hydrocortisone use in the present study, only a third (32.7%) of the children with this symptom 
were given parenteral hydrocortisone prior to presentation and approximately 40% were given oral 
hydrocortisone only, with some parents making repeated unsuccessful attempts at its administration.  
In this analysis, a record of a prodromal illness was associated with an increased use of oral stress 
dosing and a decreased use of parenteral therapy. As most of these illnesses were viral respiratory 
tract infections, this is consistent with recommended practice (3,15,16,19, 27). While the estimates of 
stress dosing cannot be used to infer the appropriateness of the decision in each circumstance in this 
study, the lower than expected use of IM hydrocortisone in the presence of vomiting suggests that 
there may be opportunities for improvement in pre-hospital management of ill children with CAH.  
There were differences between the three health services with regards to the pre-hospital use 
of both forms of stress dosing, particularly the use of IM hydrocortisone, in which there was a six-fold 
variation in usage from 7.0% to 45.8% of the presentations. Disparities between the health services 
were also observed in the use of IV hydrocortisone and the rates of hospital admission. Possible 
reasons for these differences include patients presenting at different stages at each hospital or 
differences in clinical practice between the hospitals.  Variations in the distribution of other patient 
characteristics, such as ethnicity and socioeconomic status, between the hospitals may also have 
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influenced both pre-hospital management and in-hospital care but these could not be assessed in this 
analysis. Previous studies have shown differences in outcomes according to ethnicity (9), and
 
AC 
events have been found to occur even among well-educated patients (17,28). Patients at each hospital 
in this study had all been given education on stress management, which typically involves instruction 
on stress dosing by the treating specialist, reinforcement of the steps in AC prevention at each clinic 
visit and education sessions with a specialist paediatric endocrine nurse when required. Given this, the 
effect of repeated experience of attendance at the same hospital for acute care on the use of IM 
hydrocortisone suggests that experience may have a positive and independent influence on 
management strategies used by parents who have been given education about AC prevention. Other 
health service factors, such as delays in access to definitive treatment, were not found in this study but 
have been identified in other populations as barriers to the implementation of effective treatment of 
acute illness in AI (14,28,29).   
This study reviewed the records of all patients with at least one treatment episode in a referral 
hospital over a large geographic area. Importantly, it included all attendances at Accident and 
Emergency as well as all hospital admissions.  This enabled the examination of variation in outcomes 
and management between patient subgroups and between different health services.  It is possible that 
there were some presentations of children to other non-specialist hospitals during the time frame of 
this study that could not be included in the study sample.  However, it is likely that children who were 
very unwell would have been more likely to present to a specialist service or be transferred there for 
treatment and, therefore, would have been included in this dataset.  In addition, the number of patients 
with less severe disease or those who managed episodes of illness successfully at home could not be 
determined. The AC classification used in this study was based on the clinical impression of the 
attending physician and this may have introduced some measurement error into the estimate of AC 
incidence. Further, although the data extracted from the record was validated in this study, not all 
records were complete and this differed between the hospitals.  Information regarding timeframes of 
readmission was not included in this study but is important and worthy of further investigation. 
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 In conclusion, prevention of symptomatic AI/AC remains an issue in the management of 
patients with CAH.  Importantly, the results of this investigation demonstrate that patient factors alone 
are not the sole determinants of health outcomes in CAH, and that parental experience with the 
management of illness influences the use of stress dosing even among well-educated patients. Finally, 
these results demonstrate the value of inter-hospital comparison studies for chronic diseases, such as 
CAH and emphasise the importance of the consistent, guideline based application of AC prevention 
strategies and optimal hospital management.    
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Table 1 Signs, Symptoms and Treatment of AI by Age Group for all Presentations to Paediatric 
Referral Hospitals in NSW, 2000-2015 
 
Category 
Total 
(N=321) 
Age Group (Yrs) 
N (%) P value 
<1  1-4 5-9 10-18 
  (N=81) (N=126) (N=56) (N=58)  
Males 178 (55.5) 57 (70.4) 60 (47.6)  27 (48.2) 34 (58.6) <0.01 
Admitted 213 (66.4) 55 (67.9) 74 (58.7) 38 (67.8) 46 (79.3) NS 
Diagnosis 
Any Infection    137 (42.7) 33 (40.7) 62 (49.2) 24 (42.9) 18 (31.0) NS 
        Gastroenteritis 52 (16.2) 13 (16.0) 17 (13.5) 14 (25.0) 8 (13.8) NS 
Signs and symptoms  
Diarrhoea 78 (24.3) 21 (25.9) 25 (19.8) 16 (28.6) 16 (27.6) NS 
Vomiting 196 (61.1) 40 (49.4) 86 (68.3) 39 (69.6) 31 (53.4) <0.05 
Prodromal illness  189 (58.9) 46 (56.8) 85 (67.5) 26 (46.4) 32 (55.2) 0.05 
Fever  108 (33.6) 22 (27.2) 52 (41.3) 22 (39.3) 12 (20.7) <0.05 
Hypotension  19 (5.9) 3 (3.7) 4 (3.2) 7 (12.5) 5 (8.6) NS 
Dehydration 35 (10.9) 6 (7.4) 13 (10.3) 8 (14.3) 8 (13.8) NS 
Reduced level of 
consciousness 
38 (11.8) 3 (3.7) 23 (18.3) 6 (10.7) 5 (14.3) <0.05 
Lethargy 102 (31.8) 20 (24.7) 52 (41.3) 14 (25.0) 16 (27.6) <0.05 
Hyponatreamia    41 (12.8) 13 (16.0) 16 (12.7) 7 (12.5) 5 (8.6) NS 
Hyperkalaemia  20 (6.2) 14 (17.3) 4 (3.2) 2 (3.6) 0 (0.0) <0.01 
Hypoglycaemia  27 (8.4) 5 (6.2) 14 (11.1) 5 (8.9) 3 (5.2) NS 
AC Recorded 29 (9.0) 7 (8.6) 14 (11.1) 4 (7.1) 4 (6.9) NS 
Management 
PO Stress Dosing 134 (41.7) 30 (37.0) 67 (53.2) 19 (33.9) 18 (31.0) <0.01 
IM Hydrocortisone 71 (22.1) 12 (14.8) 24 (19.0) 16 (28.6) 19 (32.8)    <0.05 
Any form of Stress Dosing 206 (64.2) 42 (51.9) 92 (73.0) 35 (62.5) 37 (63.8) <0.05 
IV Hydrocortisone 158 (49.2) 31 (38.3) 60 (47.6) 30 (53.6) 37 (63.8) <0.05 
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Table 2 Demographic characteristics, signs, symptoms and treatment of AI by hospital for all 
Presentations to Paediatric Referral Hospitals in NSW, 2000-2015 
 
Category 
Hospital          N (%) 
P Value 
Hospital A 
(N=157) 
Hospital B 
(N=57) 
Hospital C 
(N=107) 
Admissions 90 (57.3) 37 (64.9) 86 (80.4) <0.001 
Diagnosis 
Any infection 63 (40.1) 26 (45.6) 48 (44.9) NS 
      Gastroenteritis 20 (12.7) 8 (14.0) 24 (22.4) NS 
Signs and Symptoms 
Diarrhoea 39 (24.8) 8 (14.0) 31 (29.0) NS 
Vomiting 84 (53.5) 34 (59.6) 78 (72.9) <0.01 
Prodromal illness 101 (64.3) 25 (43.9) 63 (58.9) <0.05 
Fever  58 (36.9) 18 (31.6) 32 (29.9) NS 
Hypotension  11 (7.0) 1 (1.8) 7 (6.5) NS 
Dehydration 9 (5.7) 10 (17.5) 16 (15.0) <0.05 
Reduced level of consciousness 17 (10.8) 3 (5.3) 18 (16.8) NS 
Hyperkalaemia (>5.0mmol/L)  9 (5.7) 5 (8.8) 6 (5.6) NS 
Hyponatraemia (<135mmol/L)  19 (12.1) 12 (21.1) 10 (9.3) NS 
Hypoglycaemia (<3.5mmol/L) 18 (11.5) 5 (8.8) 4 (3.7) NS 
AC Recorded 6 (3.8) 6 (10.5) 17 (15.9) <0.01 
Mean AC Signs and Symptoms (SD)  1.15 (0.96) 1.14 (0.90) 1.35 (0.93)  NS 
Management 
PO Stress dosing 85 (54.1) 17 (29.8) 32 (29.9) <0.001 
IM Hydrocortisone 11 (7.0) 11 (19.3) 49 (45.8) <0.001 
Any form of Stress Dosing 96 (61.1) 29 (50.9) 81 (75.7) <0.01 
IV Hydrocortisone 62 (39.5) 22 (38.6) 74 (69.2) <0.001 
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Table 3 Signs, Symptoms and Treatment of AI by Method of Stress Dosing for all Presentations to 
Paediatric Referral Hospitals in NSW, 2000-2015 
 
Category 
 
Method of Stress Dosing 
N (%) 
 
Total 
 
PO Route IM Injection 
Males 178 63 (35.4) 39 (21.9) 
Admitted 133 79 (37.1) 53 (24.9) 
Diagnosis 
Any Infection 137 59 (44.0) 39 (54.9) 
……Gastroenteritis 52 22 (42.3) 22 (42.3) 
Signs and Symptoms 
Diarrhoea 78 40 (51.3) 19 (24.4) 
Vomiting 196 81 (41.3) 64 (32.7) 
Lethargy 102* 48 (47.1) 28 (27.5) 
Hypotension 19 9 (47.4) 7 (36.8) 
Fever 108* 50 (46.3) 25 (23.1) 
Prodromal Illness 189* 96 (50.8) 33 (17.5) 
Reduced Consciousness 38 15 (39.5) 15 (39.5) 
Dehydration 35  14 (40.0) 16 (45.7) 
Hyperkalaemia 20 5 (25.0) 4 (20.0) 
Hyponatraemia 41 19 (46.3) 9 (22.0) 
Hypoglycaemia 27 11 (40.7) 7 (25.9) 
AC Recorded 29  10 (34.5) 13 (44.8) 
Management 
IV Hydrocortisone  158* 65 (41.1) 50 (31.6) 
 
*One patient had a record of stress dosing without a specification about the type of administration. 
Therefore, the number of patients reporting any form of stress dosing do not correspond to the sum of 
the other variables.  
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Table 4 Signs, Symptoms and Treatment of AI by Admission Status for all Presentations to Paediatric 
Referral Hospitals in NSW, 2000-2015 
 
 
 
 
 
 
Category 
Admission  
N (%) 
ED Attendance 
Only  
N (%) 
P Value 
Diagnosis 
Any infection 81 (62.80) 48 (37.20) NS 
      Gastroenteritis 32 (62.70) 19 (37.30) NS 
Signs and Symptoms 
Diarrhoea 51 (65.40) 27 (34.60) NS 
Vomiting 140 (71.40) 56 (28.60) <0.02 
Prodromal illness 126 (66.70) 63 (33.30) NS 
Fever  75 (69.40) 33 (30.60) NS 
Hypotension  12 (63.20) 7 (36.80) NS 
Dehydration 27 (77.10) 8 (22.90) NS 
Reduced level of consciousness 32 (84.20) 6 (15.80) 0.01 
Hyperkalaemia (>5.0mmol/L)  14 (100.00) 0 (0.00) <0.01 
Hyponatraemia (<135mmol/L)  33 (80.50) 8 (19.50) 0.04 
Hypoglycaemia (<3.5mmol/L) 22 (81.50) 5 (18.50) NS 
AC Recorded 28 (96.60) 1 (3.4) <0.01 
Mean AC Signs and Symptoms 
(SD) 
1.35 (0.92) 0.93 (0.92) <0.001 
Management 
IV Hydrocortisone 143 (90.50) 15 (9.50) <0.01 
PO Stress dosing 79 (59.00) 55 (41.00) <0.02 
IM Hydrocortisone 53 (74.60) 18 (25.40) NS 
Any form of Stress Dosing 133 (64.60) 73 (35.40) NS 
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Table 5 Odds ratios for use of Oral and IM stress dosing, IV hydrocortisone and Admission. 
 
Variable Wald statistic OR 95% CI P value 
PO Use  
Hospital 
       A (referent) 
       B 
       C 
16.53 
- 
6.77 
14.02 
 
- 
0.41 
0.36 
 
- 
0.21-0.80 
0.21-0.62 
          <0.001 
- 
<0.01 
<0.001 
Prodromal Illness 12.74 2.43 1.49-3.96 <0.001 
IM Use  
Vomiting 18.60 7.48 3.00-18.67 <0.001 
Hospital 
       A (referent) 
       B 
       C 
34.08 
- 
4.31 
32.63 
 
- 
2.80 
9.65 
 
- 
1.06-7.41 
        4.43-21.00 
<0.001 
- 
<0.05 
<0.001 
Prodromal Illness 7.20 0.41 0.21-0.78 <0.01 
Gastroenteritis 4.71 2.34 1.09-5.03 <0.01 
Number of Attendances 7.47 1.11 1.03-1.20 <0.01 
Any Form of Stress Dosing  
Vomiting 13.16 2.50 1.52-4.10 <0.001 
Hospital 
       A (referent) 
       B 
       C 
7.56 
- 
2.63 
2.51 
 
- 
0.59 
1.59 
 
- 
0.31-1.12 
0.90-2.81 
           <0.05 
- 
NS 
NS 
Gastroenteritis 5.49 2.67 1.17-6.09 <0.05 
IV Hydrocortisone Use  
Number of AC Signs and 
Symptoms  
14.89 2.02 1.46-2.90 <0.001 
Hospital  
      A (referent) 
      B 
      C 
          13.51 
- 
0.03 
11.74 
 
- 
0.94 
2.73 
 
- 
0.48-1.87 
1.54-4.86 
           0.001 
- 
NS 
0.001 
Age (years) 12.105 1.11 1.05-1.17 0.001 
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Vomiting  4.51 1.97 1.05-3.69 0.034 
Admission 
Number of AC Signs and 
Symptoms 
12.01 1.64 1.24-2.17 0.001 
Hospital  
      A (referent) 
      B 
      C 
          10.06 
- 
1.23 
10.00 
 
- 
1.44 
2.60 
 
- 
0.76-2.75 
1.44-4.70 
           <0.01 
- 
NS 
<0.01 
Age (years) 4.10 1.10 1.00-1.128 <0.05 
 
 
